Medytox continued Tuesday to pressure Daewoong Pharmaceuticals to clarify suspicions over the origin of Nabota, the latter’s botulinum toxin (BTX) product, stating that it is ready to take all legal, civil and criminal, responsibility for its assertions if necessary.
Medytox’s demand came after Daewoong said that the complaint filed by Medytox and Allergan is only part of a strategy to keep the company from entering the Botox market, which is a common threat in the U.S. Daewoong also said it would hold Medytox accountable for its false accusations.
“The ITC investigation into Daewoong and Evolus is itself a special case as the decision was made by an attorney assigned by the ITC after close review of statements from both sides,” a Medytox official said. “Daewoong said it would hold Medytox liable for our alleged false accusations, so we urge Daewoong to follow up on their word and take immediate legal action.”
Medytox noted that it has no reason to continue the unnecessary disputes with Daewoong, which is one of the leading pharmaceutical companies in Korea.
“For the Korean bio industry to gain international credibility, however, we need to lay a foundation to recognize intellectual property acquired through long research and investment,” the Medytox official said. “As the Korean biotechnology industry is advancing to the global market, the suspicions about Daewoong’s Nabota development should be resolved clearly.”
Medytox strongly urges Daewoong to accept its request to hold an objective public debate attended by developers and related experts to resolve any doubts related to Nabota’s origin to put an end to the unnecessary controversy, he added.
<© Korea Biomedical Review, All rights reserved.>